Benign Prostatic Hypertrophy (Enlarged Prostate)
Northern California Research is conducting a study for Benign Prostatic Hypertrophy (Enlarged Prostate).
The trial is a dose-ranging study of OPK-88004, and includes a once-a-day dosing for 16 weeks in men with signs and symptoms of benign prostatic hyperplasia.
As the prostate enlarges, it can then squeeze down on your urethra. The bladder wall becomes thicker. Eventually, the bladder may weaken and lose the ability to empty completely, leaving some urine in the bladder. The narrowing of the urethra and urinary retention–the inability to empty the bladder completely–cause many of the problems associated with benign prostatic hyperplasia.
BPH is benign. This means it is not cancer. It does not cause nor lead to cancer. But BPH and cancer can happen at the same time. BPH is common in aging men. About half of all men between the ages of 51 and 60 have BPH. Up to 90% of men over age 80 have BPH.
Study requires: Ages 45 years and older. The study will last 6 months with 9 office visits to the clinic. No cost for exams such as physicals, lab test, uroflow and ultrasounds.
Compensation for completed clinic visits $725
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03297398